Immunomonitoring Core

全面的免疫学评估对于改进疫苗至关重要。最近的研究表明 强调将谱系分析纳入疫苗诱导T细胞评估的重要性 功效。免疫监测核心将提供信息(如T细胞表位、T细胞类型 在所有项目中进行研究所需的反应(抗体效价)和工具(如四聚体 通过专业知识和最先进的技术。免疫监测的主要目标 核心是：目标1：提供对流感抗原特异性T细胞谱系(EpiMax)的最新分析。 针对流感抗原(H1、HA、M2和NP)的T细胞库将在一次会议上进行全面分析 从健康人(样本核心)、流感疫苗接种对象、 和流感感染受试者(来自临床核心)。表位(针对CD4+和CD8+T细胞)、类型和 流感特异性T细胞反应的大小将被确定。目标2：提供最先进的分析 多个流感抗原特异性抗体滴度(抗体Luminex)。流感抗原(H1HA、H5 HA、M1、M2和 NP)特异性抗体将由该研究所在Luminex平台上开发的检测方法进行测量。 目的3：提供流感抗原衍生肽/人类白细胞抗原I类或II类四聚体。T细胞表位 在EpiMax分析中确定的将被测试与HLAI或II类分子的结合，而四聚体将 由Sekaly博士的实验室产生。目的4：用识别的流感抗原表位进行细胞培养 基因组免疫反应性图谱。外周血单核细胞和鼻腔冲洗液标本的整体基因表达谱 与EpiMax鉴定的T细胞表位多肽一起培养将与 微阵列核心。因此，免疫监测核心将与其他核心设施和所有 实现共同目标的项目：开发粘膜疫苗，建立生物标记物 保护豁免权。

Comprehensive immunological assessments are critical to improve vaccines. Recent studies have emphasized the importance of incorporating repertoire analysis in the assessment of vaccine-induced T cell efficacy. Immunomonitoring Core will provide the information (such as T cell epitopes, type of T cell responses, Ab titer) and tools (such as tetramers) required to perform the research in all the Projects through the expertise and state-of-the art technologies. The primary objectives of the Immunomonitoring Core are: AIM 1: To provide state-of-the-art analysis of the Flu antigen-specific T cell repertoires (EpiMax). T cell repertories specific for Flu antigens (H1 HA, M2, and NP) will be comprehensively analyzed at a peptide level with samples obtained from healthy individuals (from Sample Core), Flu-vaccinated subjects, and Flu-infected subjects (from Clinical Core). The epitopes (for CD4+ and CD8+ T cells), the type, and the magnitude of Flu-specific T cell responses will be determined. AIM 2: To provide state-of-art analysis of multiple Flu-antigen-specific antibody liters (Ab Luminex). Flu-antigen (H1HA, H5 HA, M1; M2, and NP)-specific antibodies will be measured by the assay developed at the Institute in a platform of Luminex. AIM 3: To provide Flu-antigen derived peptide/HLA class I or class II tetramers. The T cell epitopes identified in EpiMax assay will be tested for the binding to HLA class I or II molecules, and the tetramers will be generated at Dr. Sekaly's lab. AIM 4: To perform cell cultures with the identified Flu antigen epitopes for genomic Immunoreactivity profiles. Global gene expression profile of PBMCs and nasal wash samples cultured with the T cell epitope peptide identified with EpiMax will be analyzed in the collaboration with Microarray Core. Thus, Immunomonitoring Core will extensively interact with other Core facilities and all the Projects towards the common goals: development of mucosal vaccines, and establishment of biomarkers of protective immunity.